Martin Ahnoff

Papers

1

Total Citations

14

H-Index

1

About

Martin Ahnoff is a leading figure in bioanalytical chemistry, with a specialized focus on the development of highly sensitive and selective liquid chromatography–tandem mass spectrometry (LC–MS/MS) methods for drug quantification in biological matrices. His most cited work, a 2007 study on the determination of the anticoagulant ximelagatran and its active metabolite melagatran, exemplifies his expertise in mixed-mode solid-phase extraction (SPE) techniques. This paper, which has garnered 14 citations, demonstrates his ability to solve complex analytical challenges by simultaneously isolating multiple analytes—including intermediary metabolites—from plasma. Ahnoff’s contributions are pivotal for pharmacokinetic studies and therapeutic drug monitoring, enabling precise measurement of drug levels that underpin safe and effective dosing. His methodological innovations, particularly in optimizing SPE and LC–MS/MS workflows, have set standards for robustness and reproducibility in bioanalysis. Through this work, Ahnoff has advanced the field’s capacity to handle challenging drug–metabolite profiles, directly supporting pharmaceutical development and clinical research.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC–MS/MS
14 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 5

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago